Display options
Cite
Witkowski M, Tizian C, Ferreira-Gomes M, et al. Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells. Nature. 2021;600(7888):295-301doi: 10.1038/s41586-021-04142-6.
Witkowski, M., Tizian, C., Ferreira-Gomes, M., Niemeyer, D., Jones, T. C., Heinrich, F., Frischbutter, S., Angermair, S., Hohnstein, T., Mattiola, I., Nawrath, P., McEwen, S., Zocche, S., Viviano, E., Heinz, G. A., Maurer, M., Kölsch, U., Chua, R. L., Aschman, T., Meisel, C., Radke, J., Sawitzki, B., Roehmel, J., Allers, K., Moos, V., Schneider, T., Hanitsch, L., Mall, M. A., Conrad, C., Radbruch, H., Duerr, C. U., Trapani, J. A., Marcenaro, E., Kallinich, T., Corman, V. M., Kurth, F., Sander, L. E., Drosten, C., Treskatsch, S., Durek, P., Kruglov, A., Radbruch, A., Mashreghi, M. F., & Diefenbach, A. (2021). Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells. Nature, 600(7888), 295-301. https://doi.org/10.1038/s41586-021-04142-6
Witkowski, Mario, et al. "Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells." Nature vol. 600,7888 (2021): 295-301. doi: https://doi.org/10.1038/s41586-021-04142-6
Witkowski M, Tizian C, Ferreira-Gomes M, Niemeyer D, Jones TC, Heinrich F, Frischbutter S, Angermair S, Hohnstein T, Mattiola I, Nawrath P, McEwen S, Zocche S, Viviano E, Heinz GA, Maurer M, Kölsch U, Chua RL, Aschman T, Meisel C, Radke J, Sawitzki B, Roehmel J, Allers K, Moos V, Schneider T, Hanitsch L, Mall MA, Conrad C, Radbruch H, Duerr CU, Trapani JA, Marcenaro E, Kallinich T, Corman VM, Kurth F, Sander LE, Drosten C, Treskatsch S, Durek P, Kruglov A, Radbruch A, Mashreghi MF, Diefenbach A. Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells. Nature. 2021 Dec;600(7888):295-301. doi: 10.1038/s41586-021-04142-6. Epub 2021 Oct 25. PMID: 34695836.
Copy Download .nbib Format: NLM
Share it on

Nature. 2021 Dec;600(7888):295-301. doi: 10.1038/s41586-021-04142-6. Epub 2021 Oct 25.

Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells.

Nature

Mario Witkowski, Caroline Tizian, Marta Ferreira-Gomes, Daniela Niemeyer, Terry C Jones, Frederik Heinrich, Stefan Frischbutter, Stefan Angermair, Thordis Hohnstein, Irene Mattiola, Philipp Nawrath, Sophie McEwen, Silvia Zocche, Edoardo Viviano, Gitta Anne Heinz, Marcus Maurer, Uwe Kölsch, Robert Lorenz Chua, Tom Aschman, Christian Meisel, Josefine Radke, Birgit Sawitzki, Jobst Roehmel, Kristina Allers, Verena Moos, Thomas Schneider, Leif Hanitsch, Marcus A Mall, Christian Conrad, Helena Radbruch, Claudia U Duerr, Joseph A Trapani, Emanuela Marcenaro, Tilmann Kallinich, Victor M Corman, Florian Kurth, Leif Erik Sander, Christian Drosten, Sascha Treskatsch, Pawel Durek, Andrey Kruglov, Andreas Radbruch, Mir-Farzin Mashreghi, Andreas Diefenbach

Affiliations

  1. Laboratory of Innate Immunity, Institute of Microbiology, Infectious Diseases and Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany. [email protected].
  2. Mucosal and Developmental Immunology, Deutsches Rheuma-Forschungszentrum (DRFZ), an Institute of the Leibniz Association, Berlin, Germany. [email protected].
  3. Department of Microbiology and Hygiene, Labor Berlin, Charité-Vivantes, Berlin, Germany. [email protected].
  4. Laboratory of Innate Immunity, Institute of Microbiology, Infectious Diseases and Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany.
  5. Mucosal and Developmental Immunology, Deutsches Rheuma-Forschungszentrum (DRFZ), an Institute of the Leibniz Association, Berlin, Germany.
  6. Therapeutic Gene Regulation, Deutsches Rheuma-Forschungszentrum (DRFZ), an Institute of the Leibniz Association, Berlin, Germany.
  7. Institute of Virology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Charité Mitte, Berlin, Germany.
  8. German Center for Infection Research (DZIF), Partner Site Berlin, Berlin, Germany.
  9. Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, UK.
  10. Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Charité Mitte, Berlin, Germany.
  11. Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) Allergology and Immunology, Berlin, Germany.
  12. Department of Anesthesiology and Intensive Care Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany.
  13. Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Virchow-Klinikum, Berlin, Germany.
  14. Institute of Physiology, Center for Space Medicine and Extreme Environments Berlin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  15. Department of Immunology, Labor Berlin, Charité-Vivantes, Berlin, Germany.
  16. Center for Digital Health, Berlin Institute of Health (BIH) and Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  17. Department of Neuropathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  18. Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Virchow-Klinikum, Berlin, Germany.
  19. Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  20. Department of Medicine (Gastroenterology, Infectious Diseases, Rheumatology), Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Campus Benjamin Franklin, Berlin, Germany.
  21. German Center for Lung Research (DZL), Associated Partner Berlin, Berlin, Germany.
  22. Laboratory of Mucosal Immunity, Institute of Microbiology, Infectious Diseases and Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany.
  23. Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  24. Department of Experimental Medicine, University of Genoa, Genoa, Italy.
  25. Chronic inflammation in Childhood, Deutsches Rheuma-Forschungszentrum (DRFZ), an Institute of the Leibniz Association, Berlin, Germany.
  26. Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  27. Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, and Department of Medicine I, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
  28. Chronic Inflammation, Deutsches Rheuma-Forschungszentrum (DRFZ), an Institute of the Leibniz Association, Berlin, Germany.
  29. Belozersky Institute of Physico-Chemical Biology and Biological Faculty, M.V. Lomonosov Moscow State University, Moscow, Russia.
  30. Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
  31. Cell Biology, Deutsches Rheuma-Forschungszentrum (DRFZ), an Institute of the Leibniz Association, Berlin, Germany.
  32. BIH Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin Berlin, Berlin, Germany.
  33. Laboratory of Innate Immunity, Institute of Microbiology, Infectious Diseases and Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany. [email protected].
  34. Mucosal and Developmental Immunology, Deutsches Rheuma-Forschungszentrum (DRFZ), an Institute of the Leibniz Association, Berlin, Germany. [email protected].
  35. Department of Microbiology and Hygiene, Labor Berlin, Charité-Vivantes, Berlin, Germany. [email protected].

PMID: 34695836 DOI: 10.1038/s41586-021-04142-6

Abstract

SARS-CoV-2 is a single-stranded RNA virus that causes COVID-19. Given its acute and often self-limiting course, it is likely that components of the innate immune system play a central part in controlling virus replication and determining clinical outcome. Natural killer (NK) cells are innate lymphocytes with notable activity against a broad range of viruses, including RNA viruses

© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

References

  1. Diaz-Salazar, C. & Sun, J. C. Natural killer cell responses to emerging viruses of zoonotic origin. Curr. Opin. Virol. 44, 97–111 (2020). - PubMed
  2. Vivier, E., Tomasello, E., Baratin, M., Walzer, T. & Ugolini, S. Functions of natural killer cells. Nat. Immunol. 9, 503–510 (2008). - PubMed
  3. Maucourant, C. et al. Natural killer cell immunotypes related to COVID-19 disease severity. Sci. Immunol. 5, eabd6832 (2020). - PubMed
  4. Mazzoni, A. et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J. Clin. Invest. 130, 4694–4703 (2020). - PubMed
  5. Lucas, M., Schachterle, W., Oberle, K., Aichele, P. & Diefenbach, A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 26, 503–517 (2007). - PubMed
  6. Diefenbach, A. & Raulet, D. H. Innate immune recognition by stimulatory immunoreceptors. Curr. Opin. Immunol. 15, 37–44 (2003). - PubMed
  7. Zenarruzabeitia, O. et al. T cell activation, highly armed cytotoxic cells and a shift in monocytes CD300 receptors expression is characteristic of patients with severe COVID-19. Front. Immunol 12, 655934 (2021). - PubMed
  8. Zheng, M. et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell. Mol. Immunol. 17, 533–535 (2020). - PubMed
  9. Shellam, G., Allan, J., Papadimitriou, J. & Bancroft, G. Increased susceptibility to cytomegalovirus infection in beige mutant mice. Proc. Natl Acad. Sci. USA 78, 5104–5108 (1981). - PubMed
  10. Trinchieri, G. Biology of natural killer cells. Adv. Immunol. 47, 187–376 (1989). - PubMed
  11. Fehniger, T. A. et al. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity 26, 798–811 (2007). - PubMed
  12. Varchetta, S. et al. Unique immunological profile in patients with COVID-19. Cell. Mol. Immunol. 18, 604–612 (2021). - PubMed
  13. Townsend, M. J. et al. T-bet regulates the terminal maturation and homeostasis of NK and Vα14i NKT cells. Immunity 20, 477–494 (2004). - PubMed
  14. Becht, E. et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. 37, 38–44 (2019). - PubMed
  15. Freud, A. G. et al. NKp80 defines a critical step during human natural killer cell development. Cell Rep. 16, 379–391 (2016). - PubMed
  16. Yang, C. et al. Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome. Nat. Commun. 10, 3931 (2019). - PubMed
  17. Luetke-Eversloh, M., Killig, M. & Romagnani, C. Signatures of human NK cell development and terminal differentiation. Front. Immunol. 4, 499 (2013). - PubMed
  18. Huntington, N. D. et al. NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. J. immunol. 178, 4764–4770 (2007). - PubMed
  19. Sun, H. et al. Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma. Hepatology 70, 168–183 (2019). - PubMed
  20. Crinier, A. et al. High-dimensional single-cell analysis identifies organ-specific signatures and conserved NK cell cubsets in humans and mice. Immunity 49, 971–986.e5 (2018). - PubMed
  21. Hammer, Q. et al. Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells. Nat. Immunol. 19, 453–463 (2018). - PubMed
  22. Qiu, X. et al. Reversed graph embedding resolves complex single-cell trajectories. Nat. Methods 14, 979–982 (2017). - PubMed
  23. Coffman, R. L., Lebman, D. A. & Shrader, B. Transforming growth factor beta specifically enhances IgA production by lipopolysaccharide-stimulated murine B lymphocytes. J. Exp. Med. 170, 1039–1044 (1989). - PubMed
  24. Sonoda, E. et al. Transforming growth factor beta induces IgA production and acts additively with interleukin 5 for IgA production. J. Exp. Med. 170, 1415–1420 (1989). - PubMed
  25. Viel, S. et al. TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci Signal. 9, ra19 (2016). - PubMed
  26. Rook, A. H. et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. 136, 3916–3920 (1986). - PubMed
  27. Pachlopnik Schmid, J. et al. Inherited defects in lymphocyte cytotoxic activity. Immunol. Rev. 235, 10–23 (2010). - PubMed
  28. Kohl, S., Springer, T. A., Schmalstieg, F. C., Loo, L. S. & Anderson, D. C. Defective natural killer cytotoxicity and polymorphonuclear leukocyte antibody-dependent cellular cytotoxicity in patients with LFA-1/OKM-1 deficiency. J. Immunol. 133, 2972–2978 (1984). - PubMed
  29. Riteau, B., Barber, D. F. & Long, E. O. Vav1 phosphorylation is induced by β2 integrin engagement on natural killer cells upstream of actin cytoskeleton and lipid raft reorganization. J. Exp. Med. 198, 469–474 (2003). - PubMed
  30. Lee, J. S. et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci. Immunol. 5, eabd1554 (2020). - PubMed
  31. Gassen, N. C. et al. SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals. Nat. Commun. 12, 3818 (2021). - PubMed
  32. Liu, C. et al. Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19. Cell 184, 1836–1857.e22 (2021). - PubMed
  33. Travis, M. A. & Sheppard, D. TGF-β activation and function in immunity. Annu. Rev. Immunol. 32, 51–82 (2014). - PubMed
  34. Stukalov, A. et al. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. Nature 594, 246–252 (2021). - PubMed
  35. Ferreira-Gomes, M. et al. SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself. Nat. Comm. 12, 1961 (2021). - PubMed
  36. Schulte-Schrepping, J. et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell 182, 1419–1440.e23 (2020). - PubMed
  37. Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol. 20, 355–362 (2020). - PubMed
  38. van Dommelen, S. L. et al. Perforin and granzymes have distinct roles in defensive immunity and immunopathology. Immunity 25, 835–848 (2006). - PubMed
  39. Krizhanovsky, V. et al. Senescence of activated stellate cells limits liver fibrosis. Cell 134, 657–667 (2008). - PubMed
  40. Chen, W. A potential treatment of COVID-19 with TGF-β blockade. Int. J. Biol. Sci. 16, 1954–1955 (2020).  - PubMed
  41. Force, A. D. T. et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 307, 2526–2533 (2012). - PubMed
  42. Cossarizza, A. et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). Eur. J. Immunol. 49, 1457–1973 (2019). - PubMed
  43. Verneris, M. R., Karimi, M., Baker, J., Jayaswal, A. & Negrin, R. S. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8 - PubMed
  44. Bryceson, Y. T. et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 119, 2754–2763 (2012). - PubMed
  45. Deguine, J., Breart, B., Lemaitre, F., Di Santo, J. P. & Bousso, P. Intravital imaging reveals distinct dynamics for natural killer and CD8 - PubMed
  46. Wolfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465–469 (2020). - PubMed
  47. Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT–PCR. Euro Surveill. 25, 2000045 (2020). - PubMed
  48. Jones, T. C. et al. Estimating infectiousness throughout SARS-CoV-2 infection course. Science 373, eabi5273 (2021). - PubMed
  49. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018). - PubMed
  50. Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888–1902.e21 (2019). - PubMed
  51. Smith, S. L. et al. Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing. Blood Adv. 4, 1388–1406 (2020). - PubMed
  52. Young, M. D. & Behjati, S. SoupX removes ambient RNA contamination from droplet-based single-cell RNA sequencing data. Gigascience 9, giaa151 (2020). - PubMed
  53. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005). - PubMed
  54. Li, S. et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat. Immunol. 15, 195–204 (2014). - PubMed
  55. Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739–1740 (2011). - PubMed
  56. Sivori, S. et al. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell. Mol. Immunol. 16, 430–441 (2019). - PubMed

Publication Types